IAMH
NTLA icon

IvyRock Asset Management (HK)’s Intellia Therapeutics NTLA Stock Holding History

IvyRock Asset Management (HK)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
19,830
+500
+3% +$6.37K 0.14% 20
2025
Q4 		$174K Buy
19,330
+5,000
+35% +$68.8K 0.09% 21
2025
Q3 		$247K Buy
+14,330
New +$176K 0.11% 15

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IvyRock Asset Management (HK)'s NTLA Position: Q1 2026 in Review

IvyRock Asset Management (HK) increased its Intellia Therapeutics (NTLA) stake by 2.6% in Q1 2026, buying an estimated $6.37K and bringing the position to 19,830 shares worth $254K. The position accounts for 0.14% of the portfolio, ranked #20.

IvyRock Asset Management (HK) first reported a position in NTLA in Q3 2025 and has held it in 3 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • IvyRock Asset Management (HK) held 19,830 shares of Intellia Therapeutics worth $254K as of Q1 2026.
  • IvyRock Asset Management (HK) bought 500 Intellia Therapeutics shares in Q1 2026, an estimated $6.37K.
  • Intellia Therapeutics made up 0.14% of IvyRock Asset Management (HK)'s portfolio in Q1 2026, its #20 holding.
  • IvyRock Asset Management (HK) first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on IvyRock Asset Management (HK)'s 13F filing for Q1 2026, filed 7 May 2026.